Please sign in to follow a disease.
Could a simple progesterone shot replace standard IVF drugs?
NCT ID NCT07350317
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 4 trial will compare a daily shot of natural progesterone (Prolutex) against the standard drug cetrorelix for preventing early ovulation in women undergoing freeze-all IVF. About 230 women aged 18-40 will be enrolled. The goal is to see if progesterone works just as well, potentially offering a simpler and cheaper option.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- subcutaneous natural progesterone (Prolutex)
- What this could lead to
- If successful, this could offer a simpler, more cost-effective alternative to current medications for preventing early ovulation during IVF.
- What could go wrong
- This is an early-stage comparison of two approved drugs, so the new use may not prove as effective. The trial is small (230 participants) and not yet recruiting, so results are uncertain.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 4
Runs after approval, following long-term safety and how well the treatment works in everyday use.
- Participants
-
About 230 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jan 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 40 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Women aged 18-40 years. 2. Body Mass Index \< 35 kg/m² 3. Antral Follicle Count ≥ 8 or Anti-Müllerian Hormone ≥ 1.2 ng/mL 4. Undergoing freeze-all IVF (for Ovarian Hyperstimulation Syndrome - OHSS risk, PGT- Preimplantation Genetic Testing, or personal preference) Exclusion Criteria: 1. Poor responders (Bologna criteria) 2. Stage III-IV endometriosis 3. Pituitary or hypothalamic dysfunction 4. Planned fresh embryo transfer 5. Severe Male Factor. Semen Count \<1 ×〖10〗\^6 (\<1 Million/ml) or Azoospermia)
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Assisted reproductive techniques are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.